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Abstract
GCA is the most common form of primary systemic vasculitis affecting older people. It is considered a clinical
emergency because it can lead to irreversible blindness in around 20% of untreated cases. High doses of gluco-
corticoids should be initiated promptly to prevent disease-related complications; however, glucocorticoids therapy
usually results in significant toxicity. Therefore, correct diagnosis is crucial. For many years, temporal artery biopsy
has been considered the diagnostic ‘gold standard’ for GCA, but it has many limitations (including low sensitivity).
US has proven to be effective for diagnosing GCA and can reliably replace temporal artery biopsy in particular clin-
ical settings. In cases of suspected GCA with large-vessel involvement, other imaging modalities can be used for
diagnosis (e.g. CT and PET). Here we review the current evidence for each diagnostic modality and propose an al-
gorithm to diagnose cranial-GCA in a setting with rapid access to high quality US.
Key words: giant cell arteritis, diagnosis, temporal artery biopsy, ultrasound, magnetic resonance, computed
tomography, positron emission tomography, imaging
Introduction
GCA is the most common form of primary systemic vas-
culitis in patients aged >50 years. It occurs predominantly
in the northern latitudes, mainly affecting Caucasians,
with an overall annual incidence of 15–25 per 100 000
individuals older than 50 years [1]. Its incidence increases
with age, peaking between 70–80 years, and it is more
common in women than men, in a 2–4:1 proportion [2, 3].
The vasculitic process in GCA affects large- and
medium-sized blood vessels with predisposition for the in-
volvement of cranial arteries derived from the carotid ar-
tery [4]. Due to the intense myointimal proliferation and
vessel occlusion, major ischaemic events may occur in
this disease, such as arteritic anterior ischaemic optic
neuropathy, which can result in irreversible blindness.
Treatment with high doses of glucocorticoids (GCs)
should be initiated as early as possible to rapidly control
disease manifestations and prevent complications.
However, GC therapy may cause various adverse effects,
previously reported in over 80% of patients [5], particularly
in the period shortly following GC initiation [6]. Therefore,
the need for a correct diagnosis is essential in GCA.
Here we will review the clinical features that should
raise suspicion for GCA, current diagnostic modalities
[temporal artery biopsy (TAB), US and other imaging
techniques]), and diagnostic and classification criteria,
and propose a diagnostic approach to patients with sus-
pected GCA.
Clinical manifestations
The most frequent symptoms and signs of GCA are
related to the disease involvement of cranial arteries,
predominantly the temporal artery. New onset of head-
ache, particularly in the temporal region, is the most
common symptom of the disease [7], and jaw claudica-
tion is the most specific manifestation [8]. Scalp tender-
ness and visual disturbances can also be present; scalp
necrosis and tongue claudication or necrosis occur less
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commonly. On physical examination, temporal arteries
may be tender or thickened on palpation, and pulses
diminished or absent (Fig. 1). GCA-related severe cranial
ischaemic events include blindness, which can occur in
15–20% of patients, often secondary to anterior is-
chaemic optic neuropathy [9, 10], and cerebrovascular
accidents (transient ischaemic attack or stroke) present
in 3–7% of cases [11–13]. Given that these serious
events may frequently occur at disease onset, GCA is
considered to be a medical emergency [14]. Patients
with a suspected diagnosis of cranial GCA should be
immediately referred for specialist care, but the initiation
of treatment should not be delayed by diagnostic proce-
dures such as TAB or imaging [15].
Extra-cranial involvement in GCA affecting the aorta
and its major branches, also known as large-vessel
GCA (LV-GCA), has been described in 20–80% of
cases, depending upon the imaging modality used for
screening the disease [16–18]. These patients can be ei-
ther asymptomatic or present with limb claudication,
vascular bruits and decreased or absent pulses [19].
Late potential complications include valvular heart dis-
ease and aortic aneurysms and/or dissections [20–22].
Although very non-specific, systemic symptoms such
as fatigue, low-grade fever and weight loss are often
present in patients with a diagnosis of GCA. In addition,
PMR, characterized by pain and morning stiffness
particularly in the shoulders and hips, occurs in about
40–60% of patients with GCA, and 16–21% of patients
with the diagnosis of PMR have, or will develop,
GCA [23].
High levels of inflammatory markers are present in the
majority of patients with GCA at disease presentation.
However, in cases of localized disease, without constitu-
tional symptoms, ESR and CRP values may be within
the normal range, and this subgroup of patients are
known to be at higher risk of developing ocular ischae-
mic complications [24–26].
A summary of the clinical features and frequencies in
which they occur in GCA can be found in Table 1.
Temporal artery biopsy
GCA was historically believed to be confined to the cra-
nial arteries; therefore, for many years, TAB was consid-
ered to be the diagnostic ‘gold standard’. TAB should
be performed by an experienced surgeon, in order to
obtain good quality biopsy samples, and preferably
within the first 7 days of treatment initiation, in order to
enhance its sensitivity [29]. The optimal length of the bi-
opsy specimen remains debatable. Segments of at least
0.5–1 cm post-formalin fixation are considered accept-
able in various studies [29–32]. In practical terms, this
requires harvesting biopsies around 1.5 cm in length to
allow for an estimated 10% tissue shrinkage during fix-
ation [33]. TAB should be obtained from the most symp-
tomatic site; US guidance in TAB has failed to show
improvement in the sensitivity for diagnosing GCA [34].
Moreover, biopsy of the contralateral artery has been
reported to only increase the diagnostic yield by 4–13%
[35–39] and is therefore not routinely recommended.
TAB has the advantage of aiding correct differential
diagnosis between GCA and other diseases (e.g.
FIG. 1 Swollen right temporal artery (frontal branch) of a
patient with GCA
TABLE 1 Clinical and laboratory features of GCA
Clinical feature Frequency (%)
Elevated ESR and/or elevated CRP 90–95
Headache 70–90
Audiovestibular manifestations (hearing





fever, fatigue or weight loss)
30–60
Abnormal temporal artery on physical





Visual disturbances (transient or
permanent)
20–50
Visual loss due tob:
Anterior ischaemic optic neuropathy 91
Central retinal artery occlusion 11
Cilioretinal artery occlusion 10
Posterior ischaemic optic neuropathy 4








aBased on a study from Amor-Dorado et al. 2003 [27].
bBased on a study from Hayreh et al. 2002 [28].
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ANCA-associated vasculitis, amyloidosis, etc.). In add-
ition, distinct histopathological features of TAB have
been associated with different clinical manifestations of
the disease, suggesting a potential prognostic value for
this diagnostic method [40–43]. The classic histological
picture of GCA is a transmural inflammatory infiltrate
associated with marked disruption of the internal elastic
lamina and the presence of giant cells. However, TAB
may contain less obvious characteristics of the disease,
such as periadventitial/vasa vasorum restricted inflam-
mation or intimal hyperplasia, which make the histologic
diagnosis less straightforward [44–46]. An inter-rater
analysis for biopsy results was conducted in the multi-
centre TABUL (Temporal Artery Biopsy vs ULtrasound in
diagnosis of GCA) study, revealing a large amount of
variability in agreement between pathologists. A total of
30 cases were reviewed by 14 pathologists and only in
11 cases did all pathologists agree on the results (con-
sistent vs not consistent with GCA), which corresponded
to an intra-class correlation coefficient of 0.62 (95% CI
0.49, 0.76) [29]. Thus, it is vital to interpret TAB results
with caution, and to establish good communication be-
tween clinicians and pathologists.
Despite the high specificity of TAB for diagnosing
GCA (up to 100%), sensitivity can be as low as 39%
mainly due to poor sampling (it is estimated that around
7% of all TABs may not actually consist of arterial tissue
[29]); reduced accessibility to the procedure; the seg-
mented nature of the pathological findings, also
described as ‘skip lesions’ [47]; and the presence of LV-
GCA, which is known to have less temporal arterial in-
volvement of the disease [48]. In addition, although TAB
is regarded as a generally safe procedure, it is still an in-
vasive technique with an associated complication rate of
0.5% [49], with the most serious complications
reported including facial nerve injury [50–55] and scalp
necrosis [56]. Therefore, less invasive options with




In 1997, Schmidt et al. described for the first time the
importance of temporal artery US in the diagnosis of
GCA, based on the presence of a homogeneous, hypoe-
choic wall thickening, known as the ‘halo sign’ (Fig. 2)
[57, 58]. Stenoses and occlusions, although less specific
for GCA, may also be found in patients with this diagno-
sis. More recently, incompressibility of the temporal ar-
tery upon application of pressure with the US probe,
termed as the ‘compression sign’, has been reported to
have a positive predictive value of 100% for GCA diag-
nosis [59, 60]. Many studies, particularly in the past two
decades, have investigated the diagnostic accuracy of
various US findings in GCA [61]. Table 2 summarizes
the results of five meta-analyses that have addressed
this issue so far [3, 62–65], in which US yields an overall
sensitivity of 68–88% and specificity of 77–91%, in com-
parison with TAB, for the diagnosis of GCA. The TABUL
study assessed the diagnostic accuracy and cost-
effectiveness of US and TAB in a prospective
multicentre cohort study, using a clinical diagnosis as
reference standard [29]. A total of 381 patients under-
went both US and TAB in the first 10 days of commenc-
ing high doses of GCs (>20 mg of prednisolone or
equivalent per day). US showed a sensitivity of 54% and
specificity of 81% for GCA diagnosis, whereas TAB had
a sensitivity of 39% and specificity of 100%. Of note,
TAB was part of the reference standard, thus the 100%
specificity might have been heavily influenced by study
methodology. A combination strategy using both modal-
ities in sequence, with all patients undergoing US, but
only performing TAB in negative cases, increased the
sensitivity to 65% and maintained specificity at 81%
(decreasing the need for TAB by 43%). However, the
best and most cost-effective diagnostic strategy, with
an incremental net monetary benefit of £485 per patient,
consisted of further combination with clinical judgement.
Only in cases of high clinical suspicion, but a negative
US, should TAB be considered, leading to a sensitivity
of 93% and specificity of 77%.
US should be performed with high quality equipment,
by experienced ultrasonographers, and in a timely man-
ner [15, 66]. Most modern US machines are able to pro-
vide a resolution of 0.1 mm and thus are very sensitive
to detect the halo sign, which is estimated to measure
>0.29–0.42 mm in the temporal arteries and >1.0 mm in
the axillary arteries [67]. The halo sign and compression
sign have been regarded by the OMERACT Large
Vessel Vasculitis Ultrasound Working Group as the most
important US findings suggestive of vasculitis, and the
presence of the halo sign to be a minimum requirement
to diagnose GCA [58]. In addition, detection of the halo
sign rapidly diminishes following treatment [68] and it
has been reported to disappear after a mean of 2–
10 weeks [57, 69–71]; therefore, US should be per-
formed as early as possible after symptom onset. Two
retrospective studies have shown that a fast-track
FIG. 2 US of a patient with GCA showing a ‘halo sign’ in
the temporal artery
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approach to patients with suspected GCA, providing
clinical and ultrasonographic evaluation within 24 h, can
reduce the rate of permanent visual loss compared with
conventional referral [72, 73], as well as avoiding un-
necessary use of high-dose GCs in patient who do not
have GCA.
US of the temporal 6 axillary arteries is recommended
by the EULAR as the first imaging modality in patients
suspected to have predominantly cranial GCA. Extra-
cranial US may be used to diagnose LV-GCA, but is of
limited value to assess the aorta [15]. In comparison
with TAB, US has the advantage of being a more ac-
cessible and safer procedure, with the ability to assess
several arterial territories at the same evaluation, provide
immediate results to the clinician and be repeated in
cases of suspected disease activity [74]. However, it is
operator and machine dependent, and the final ultra-
sonographic diagnosis of GCA is highly dependent upon
the presence or absence of the halo sign in any arterial
segment assessed. Like in other diseases (e.g. RA [75]),
an ultrasonographic scoring system is needed to im-
prove GCA assessment. In 2014, a semi-quantitative
score, based on the extent and severity of the halo sign
in temporal and axillary arteries, was proposed by Brier
et al. [76]. Recently, Monti and colleagues developed a
quantitative score, combining ultrasonographic findings
(maximum intima-media thickness and bilaterality of the
halo sign at the level of the temporal and axillary
arteries) and clinical features of the disease (ischaemic
symptoms, elevated CRP or ESR and presence of
PMR), to stratify patients according to the risk of having
a positive TAB, supporting the use of US as a surrogate
for TAB [77].
Very-high resolution US (frequency 55 MHz, axial reso-
lution 0.045 mm) has recently been reported to provide
improved assessment of the temporal arteries, with su-
perior distinction of the intima, media and adventitia
layers, compared with conventional US (frequencies
<25 MHz), in patients with GCA [78]. It is expected that
in the near future, with advances in technology and
widespread use of improved US machines, research
conducted with very-high resolution US will increase, as
well as the reported sensitivity and specificity of US to
diagnose GCA.
TABLE 2 Results of five meta-analyses assessing the performance characteristics of US abnormalities to diagnose GCA








Karassa et al. 2005 [62]
Halo sign TAB 14 (532) 69 (57, 79) 82 (75, 87)
Stenosis or occlusion TAB 15 (813) 68 (49, 82) 77 (65, 85)
Halo sign, stenosis or occlusion TAB 7 (332) 88 (74, 95) 78 (71, 84)
Halo sign ACR criteria 7 (1092) 55 (36, 73) 94 (82, 98)
Stenosis or occlusion ACR criteria 4 (933) 66 (32, 89) 95 (78, 99)
Halo sign, stenosis or occlusion ACR criteria 3 (853) 87 (80, 91) 96 (89, 98)
Arida et al. 2010 [63]
Unilateral halo sign ACR criteria 8 (575) 68 (61, 74) 91 (88, 94)
Bilateral halo sign ACR criteria 4 (380) 43 (NR) 100 (NR)
Ball et al. 2010 [3]
Halo sign TAB 9 (357) 75 (67, 82) 83 (78, 88)
Halo sign, stenosis or occlusion TAB 9 (397) 83 (77, 89) 82 (77, 87)
Halo sign ACR criteria 6 (401) 69 (60, 77) 89 (84, 92)
Halo sign, stenosis or occlusion ACR criteria 7 (571) 78 (72, 84) 88 (84, 91)
Halo sign, stenosis or occlusion TAB and/or ACR criteria
(no steroids before imaging)
5 (237) 75 (65, 84) 88 (82, 93)
Halo sign, stenosis or occlusion TAB and/or ACR criteria
(steroids before imaging)
7 (492) 72 (65, 79) 87 (82, 90)
Duftner et al. 2018 [64]
Halo sign Clinical diagnosis 8 (605) 77 (62, 87) 96 (85, 99)
Halo sign, stenosis or occlusion Clinical diagnosis 3 (560) 78 (57, 90) 89 (78, 95)
Compression sign Clinical diagnosis 2 (140) a a
Halo sign TAB 7 (289) 70 (56, 81) 84 (73, 91)
Halo sign or stenosis TAB 2 (50) 77 (23, 97) 91 (75, 97)
Halo sign, stenosis or occlusion TAB 5 (611) 78 (48, 93) 91 (70, 98)
Rinagel et al. 2019 [65]
Halo sign TAB 20 (1096) 68 (57, 78) 81 (75, 86)
Halo sign, stenosis or occlusion TAB 11 (1061) 78 (64, 87) 79 (73, 85)
aModel failed to converge. The same research group published both studies having five patients in common; sensitivities
and specificities reported were 77–79% and 100%, respectively. Clinical diagnosis: final diagnosis made according to the
ACR criteria or physician diagnosis; NR: not reported; TAB: temporal artery biopsy.
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Other imaging modalities
In patients with predominantly cranial GCA, high-
resolution MRI of the scalp arteries may be used as an
alternative diagnostic modality for GCA, particularly if US
is not available or US results are not conclusive [15].
Several studies, using 1.5-T and 3-T MRI scanners, have
assessed the diagnostic value of wall thickening and con-
trast enhancement in the temporal, occipital and intracra-
nial arteries of patients with suspected GCA [79–86]. A
meta-analysis comparing MRI with TAB and clinical diag-
nosis of GCA reported a pooled sensitivity and specificity
of 93% (95% CI 89, 96%) and 81% (95% CI 73, 81%),
and of 73% (95% CI 57, 85%) and 88% (95% CI 81,
92%), respectively [64]. Normal MRI of the cranial arteries
has been strongly associated with a normal TAB, with a
negative predictive value of 98% [86]. Therefore, it has
been proposed that MRI could be used as the initial diag-
nostic tool, with TAB being reserved only for cases with
abnormal MRI results. However, MRI should be per-
formed within the first 5 days of GC initiation in order to
avoid decrease in sensitivity [83], which may not feasible
in many centres. In addition, the high cost of MRI, the ne-
cessary expertise required in the interpretation of results
and patients’ potential adverse reactions to contrast
agents or claustrophobia may further restrict the wide-
spread use of this diagnostic modality. Recently, Goll et
al. [87] have explored the use of 7-T cranial MRI in three
patients with GCA, reporting improved image quality with
detailed visualization of the vasculitic changes, in com-
parison with 3-T cranial MRI. Thus, like with US, ongoing
technological progress may improve the diagnostic per-
formance of cranial MRI in the future.
In the latest EULAR guidelines for the use of imaging in
large-vessel vasculitis, CT and PET were not recom-
mended for the evaluation of cranial GCA [15], mainly
due to insufficient spatial resolution of these imaging
modalities and high fluorodeoxyglucose (FDG) uptake in
the brain during PET obscuring the assessment of tem-
poral arteries. However, a recent retrospective case–con-
trol study, including a small number of patients with the
diagnosis of GCA (n¼14), identified temporal artery
abnormalities on cranial CT angiography suggestive of
the disease, particularly blurred vessel wall margins and
perivascular enhancement, yielding a sensitivity of 71%
(95% CI 42, 92%) and a specificity of 86% (95% CI 57,
98%) when compared with clinical diagnosis [88]. In add-
ition, recent reports with newer generation PET-CT scan-
ners have demonstrated the detection of vasculitis in the
temporal, occipital, maxillary and vertebral arteries [89–
94]. Therefore, as research in this area continues to
evolve, CT and PET may be incorporated into future rec-
ommendations for diagnostic assessment of cranial GCA.
When there is a clinical suspicion of LV-GCA, imaging
assessment of the extra-cranial arteries should be consid-
ered. The diagnostic procedure of choice is still unclear
and mainly based on local settings and expertise. US,
MRI, CT and/or PET may be used; conventional angiog-
raphy has been superseded and is currently considered
only to be of historical interest in the diagnosis of
GCA [15]. MRI has an important role in the detection of
early signs of vasculitis, particularly wall thickness and en-
hancement, before arterial complications occur; however,
dissociation between inflammatory markers, or clinically
defined disease activity, and presence of mural contrast
enhancement has been described, potentially as a result of
vascular remodelling and persistence of neovessels [95–
97]. As in cranial-GCA, diagnostic sensitivity of MRI for LV-
GCA has been reported to rapidly reduce after 5 days of
GC treatment [98]. CT is useful to visualize mural thicken-
ing, but has the disadvantage of exposing patients to ioniz-
ing radiation [99]. Lariviere et al. reported a sensitivity of
73% (95% CI 45, 92%) and a specificity of 78% (95% CI
40, 97%) to diagnose GCA with this imaging modality
[100]. Both MRI and CT can detect structural lesions, such
as stenosis, occlusions and aneurysms; however, CT is
more accessible and enables better spatial resolution, and
image acquisition takes less time in comparison with MRI
[101]. 18F-FDG-PET is useful to evaluate the presence of
LV-GCA, with a higher sensitivity for early vascular inflam-
mation when compared with MRI or CT [100, 102]. In add-
ition, identification of distinct distribution patterns of FDG
uptake (e.g. in shoulders, hips and spinous processes) can
contribute to the diagnosis of concomitant PMR [103, 104].
The combination of PET with CT improves the identification
of anatomic areas and the differential diagnosis with ath-
erosclerosis (Fig. 3). Different methods (e.g. visual or semi-
quantitative) have been used to define the presence of vas-
cular inflammation in FDG-PET. Grading of vascular uptake
based on liver uptake appears to provide a high degree of
diagnostic accuracy [105, 106]. Two meta-analyses looking
at the diagnostic performance of PET or PET-CT specifical-
ly in patients with GCA reported a pooled sensitivity of
80% (95% CI 63, 91%) and 90% (95% CI 79, 96%), and
a pooled specificity of 89% (95% CI 78, 94%) and 98%
FIG. 3 PET-CT of a patient with LV-GCA showing vascu-
lar uptake (aorta and subclavian and axillary arteries)
LV-GCA: large-vessel GCA.
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(95% CI 94, 99%), respectively [106, 107]. One of the
major advantages of PET is the ability to identify alternative
diagnoses, such as infection or malignancy. This can be
particularly useful in patients with PMR and poor response
to standard doses of GCs, where underlying malignancy or
GCA is suspected, or in patients that present with unex-
plained constitutional symptoms and high levels of inflam-
matory markers, without any specific feature of GCA, in
whom a correct differential diagnosis is essential. The diag-
nostic performance of PET has been reported to remain
unchanged within the first 3 days of GC treatment, but with
a significant decrease after 10 days of GCs [108]. In many
centres it is difficult to perform this examination at short
notice; PET will therefore not be a good option if patients
also have cranial features of the disease (where treatment
cannot be delayed or withdrawn due to possible ischaemic
complications). Other limitations of PET include high costs
and exposure to radiation. In addition, blood glucose levels
should be <7 mmol/l (126 mg/dl) for good sensitivity [15].
Diagnostic and classification criteria
There are no diagnostic criteria for GCA. Classification
criteria were developed in 1990, by the ACR, with a
positive threshold of three out of five criteria (age
>50 years, headache, temporal artery abnormality on
examination, high ESR and abnormal TAB) [109].
However, these criteria were designed to differentiate
GCA from other vasculitides, not from non-vasculitic dis-
eases, and therefore are not suitable for diagnosis and
have been reported to perform poorly when applied to
this effect [110]. In addition, the 1990 ACR criteria were
established before the widespread use of advanced vas-
cular imaging modalities, only took into account cranial
features of the disease and followed the ‘number of cri-
teria’ rule, in which each criterion had equal weight as a
classifier despite its importance. Therefore, between
January 2011 and December 2017, a multinational, ob-
servational study, with the aim of developing diagnostic
criteria and update classification criteria for systemic
vasculitis, was conducted: The Diagnostic and
Classification Criteria for Vasculitis study [111]. Draft
revised classification criteria for GCA have already been
presented [112]. They consisted of differently weighted
criteria with a threshold score, and included typical clin-
ical symptoms of GCA, abnormalities on temporal artery
examination, high levels of inflammatory markers, abnor-
mal TAB and specific patterns of imaging findings
(including temporal artery halo on US or FDG-PET activ-
ity throughout the aorta). Full publication is expected
soon.
A proposed diagnostic approach
As discussed previously, in case of suspected GCA,
treatment should be started promptly to prevent the oc-
currence of ischaemic complications, such as blindness.
However, it is crucial to ensure correct diagnosis to
avoid overtreatment. Many discussions on whether
imaging, particularly US, is an appropriate surrogate for
TAB in the diagnosis of GCA have taken place, particu-
larly in the last decade [113, 114]. Despite TAB’s many
limitations already highlighted (low sensitivity for diagno-
sis, disagreement between pathologists, lack of immedi-
ate results, etc.) it is still considered by the majority of
the scientific community to be the diagnostic ‘gold
standard’ for GCA. Our opinion is that imaging and TAB
are complementary, and in a setting where imaging is
readily available with correct expertise, it should be the
first modality of choice to diagnose GCA, given the
prompt availability of the results, possibility to evaluate
other potential vasculitic arteries and non-invasive as-
sessment of patients at low cost. This is also supported
by the recent EULAR recommendations on the use of
imaging in large-vessel vasculitis [15] and the EULAR
guidelines on management of large vessel vasculitis
[115].
When the initial suspicion is of cranial-GCA, US of the
temporal 6 axillary arteries should be the first imaging
modality. Cranial MRI could be an alternative, but is
restricted to few centres with expertise on this imaging
technique and that can support its high costs. In cases
of positive US, if the patient already has a high clinical
suspicion of GCA (e.g. jaw claudication, anterior ischae-
mic optic neuropathy, high inflammatory marker levels,
etc.), the diagnosis of GCA can be established without
further testing (TAB or subsequent imaging) [15, 116]. In
cases of positive US, but with low to medium clinical
suspicion of GCA (e.g. unspecific headache, age
<60 years, low inflammatory marker levels, etc.) and
where other more obvious diagnoses have been
excluded (e.g. ANCA-associated vasculitis, malignancy,
etc. [117]), the authors advise a critical review of the
imaging results. It is important to consider if the examin-
ation was performed by an experienced ultrasonograph-
er (usually considered as such if >300 vascular
examinations have been previously performed), and
whether the halo sign was found bilaterally, in many ar-
tery branches and with a high maximum intima-media
thickness [63, 77, 118]. If there is strong ultrasonograph-
ic evidence of GCA, the authors propose that further
testing is unnecessary to confirm the diagnosis.
However, if the US results appear to be less certain,
TAB should be performed (or cranial MRI, depending on
the setting). On the other hand, in cases of negative US,
if the patient has a low clinical suspicion of GCA, no fur-
ther testing is necessary to exclude GCA and an alterna-
tive diagnosis should be sought [15, 116]. However, in
cases of negative US, but with medium to high clinical
suspicion of GCA, the authors advise further review the
imaging results and additional efforts to safely exclude
GCA (e.g. TAB or further imaging). This is particularly
important for cases of GCA where inflammation in TAB
is restricted to the vasa vasorum or peri-adventitial small
vessels, in which the frequency of positive US has been
reported to be significantly lower compared with those
with classic transmural inflammation in TAB [40, 119].
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In addition, it is important to remember that in the ma-
jority of studies the specificity of US was higher than its
sensitivity to diagnose GCA; therefore, we can more
comfortably diagnose GCA based on a positive US test,
than exclude this disease based on a negative examin-
ation. A proposed algorithm to diagnose cranial-GCA in
centres with rapid access to high-quality US can be
seen in Fig. 4. In centres where imaging is not readily
available and TAB is performed rapidly and with a high
level of expertise, one may consider adapting the pro-
posed algorithm, placing TAB as the first test; however,
given the low sensitivity of histology reported in the
diagnosis of GCA (39% in the TABUL study [29]), in
case of negative TAB, we advise looking for further
ways to safely exclude GCA (e.g. imaging), regardless of
the pre-test probability.
For patients in whom a diagnosis of LV-GCA is sus-
pected, the diagnostic approach will depend on local
expertise and imaging availability. In addition, patients
with LV-GCA may or may not have cranial features of
the disease; therefore, if cranial involvement is present,
the initial diagnostic approach should follow the same
principles as described for cranial-GCA. In cases of sus-
pected LV-GCA without cranial manifestations (e.g.
patients with PMR non-responders to standard doses of
GCs, presenting with constitutional features, high inflam-
matory marker levels or abnormalities in peripheral
pulses), patients should undergo imaging. US would be
the first imaging modality of choice for many centres
with high expertise in this technique, particularly given
its low cost and generally rapid access. US can reliably
assess axillary arteries, which are very frequently
involved in GCA [17, 120, 121]; however, it is of limited
use to evaluate the thoracic aorta, another commonly
involved arterial segment in GCA [122]. If US is negative,
MRI, CT or PET can be used; although PET seems to
be the most sensitive examination to assess inflamma-
tion, it has the disadvantage of rapidly decreasing its
sensitivity for diagnosis after 3 days of steroids [108],
making it unfeasible to perform in many centres. The
question remains in cases where US is positive for LV-
GCA: should another subsequent imaging modality be
performed specifically to evaluate the thoracic aorta?
Blockmans et al. reported that patients with GCA who
had increased FDG uptake in the aorta during the acute
phase of the disease were more prone to develop thor-
acic aortic dilatation during late follow-up [123].
However, there are no current recommendations regard-
ing the need for screening the aorta at baseline after the
diagnosis of GCA as already been established [15].
Conclusion
The evaluation of a patient with suspected GCA should
be performed quickly in order to avoid potential ischae-
mic complications, such as visual loss. The clinician
must investigate all the features of the disease, bearing
in mind the high specificity for GCA of some of the less
common clinical features such as jaw claudication or
arteritic anterior ischaemic optic neuropathy. Further in-
vestigation should not delay treatment initiation.
Clinicians should make all efforts to confirm the diag-
nosis of GCA. The current cheapest, fastest and safest
way to diagnose GCA in many centres is by performing
US, and depending on the clinical setting this diagnostic
modality may preclude the need for TAB. Imaging will
FIG. 4 A proposed algorithm to diagnose cranial-GCA in centres with rapid access to high quality US
Cranial symptoms      Age > 50 years         High ESR/ CRP
Clinical suspicion of cranial-GCA
Assess clinical probability for GCA
US of the temporal ± axillary arteries
PosiveNegave
Medium/High














cMRI: cranial MRI; TAB: temporal artery biopsy.
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be part of the new classification criteria for GCA and will
likely play an increasingly significant role in the assess-
ment of these patients at onset and over the course of
their disease. As technology evolves, newer generation
PET-CT machines, very-high resolution US probes, and
superior MRI and CT scanners will improve the diagnos-
tic performance of imaging. The challenge will then be
to balance the benefit of their use with the associated
costs.
Although there are currently many diagnostic tests
available, a personalized approach to the diagnosis of
GCA based on clinical manifestations, accessible
modalities and expertise should ultimately be the clini-
cian’s goal in daily practice.
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LM et al. Temporal headache and jaw claudication may
be the key for the diagnosis of giant cell arteritis. Med
Oral Patol Oral Cir Bucal 2018;23:e290–4.
9 Salvarani C, Cimino L, Macchioni P et al. Risk factors
for visual loss in an Italian population-based cohort of
patients with giant cell arteritis. Arthritis Rheum 2005;
53:293–7.
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